PT-141 is a peptide that was originally discovered by accident during research into tanning compounds, but scientists quickly realized it had a remarkable effect on sexual desire. Unlike Viagra and similar drugs that work by increasing blood flow to your genitals, PT-141 works directly in your brain to boost your actual desire for sex. Think of it as the difference between fixing the plumbing versus turning up the thermostat on your libido. It's FDA-approved for women with low sexual desire, but people of all genders use it to enhance their sexual experiences.
When you take PT-141, it travels to your brain and activates specific receptors in areas that control sexual motivation and pleasure, particularly in your hypothalamus. It's like pressing the "on" switch for your brain's reward system. These receptors then trigger a cascade of effects: your brain releases more dopamine, which makes you feel motivated and excited, while also activating the neural pathways that create physical arousal. Because it's working at the source in your brain rather than just addressing the mechanical aspects, PT-141 can help with both the mental and physical components of sexual response, making you genuinely want sex rather than just making it physically possible.
Dosage Information
Typical Dose
1.75 mg
Frequency
As needed, at least 45 minutes before activity
Administration
Subcutaneous injection
Half-Life
2–3 hours
Notes
FDA-approved dose is 1.75mg. Do not use more than once within 24 hours or more than 8 times per month. Onset typically 45-60 minutes. Nausea is common on first use.
Why this matters
Effects on sexual function last 6–12 hours despite moderate half-life.
Protocol cycle
Dose Calculator
Calculate your draw amount for an insulin syringe (U-100)
Draw to the
70
unit mark
Draw 70 units for your 1750mcg dose of PT-141
This calculator is for educational purposes. Always verify your calculations and consult a healthcare professional.
Where does PT-141 sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.79
Compound Data
Molecular Formula
C50H68N14O10
Molecular Weight
1025.20 g/mol
IUPAC Name
(3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid
PubChem CID
9941379Potential Side Effects
PT-141 discussions
Stacking Compatibility
Quick Facts
- Administration
- Subcutaneous injection
- Typical Dose
- 1.75 mg
- Frequency
- As needed, at least 45 minutes before activity
- References
- 2 curated + 48 from PubMed
- Clinical Trials
- 10 registered
- Evidence Score
- 0.8 / 100
Frequently Asked Questions about PT-141
What is PT-141?
PT-141 (Bremelanotide) is a melanocortin receptor agonist originally developed from Melanotan II research and FDA-approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the first pharmacological treatment for female sexual dysfunction. Unlike PDE5 inhibitors that work on blood vessel mechanics PT-141 acts centrally in the brain on the melanocortin system to directly enhance sexual desire and arousal in both men and women. It has a strong clinical evidence base from its FDA approval pathway and is widely used off-label for sexual enhancement in both sexes.
How does PT-141 work?
PT-141 acts as a non-selective melanocortin receptor agonist with affinity for MC1R MC3R MC4R and MC5R receptors. Its sexual function effects are primarily mediated through MC3R and MC4R activation in the hypothalamus and limbic system — brain regions controlling sexual motivation reward and arousal. Unlike erectile dysfunction drugs that act peripherally on blood vessels PT-141 works centrally to increase sexual desire at the neurological level. MC4R activation in the paraventricular nucleus of the hypothalamus increases dopamine release in mesolimbic reward circuits and activates the autonomic nervous system pathways that produce genital arousal. This central mechanism means PT-141 can be effective for both psychological and physiological components of sexual dysfunction.
What is the recommended dosage for PT-141?
The typical dose is 1.75 mg. As needed, at least 45 minutes before activity. Administration: Subcutaneous injection. FDA-approved dose is 1.75mg. Do not use more than once within 24 hours or more than 8 times per month. Onset typically 45-60 minutes. Nausea is common on first use.
What are the side effects of PT-141?
Nausea (very common on first use). Facial flushing. Headache. Injection site reaction. Temporary skin darkening. Nausea (very common — most significant side effect). Flushing (common). Headache (common). Transient blood pressure decrease (common — avoid in cardiovascular disease). Hyperpigmentation with repeated use (uncommon). Injection site bruising (uncommon). Nausea (very common — most significant limiting side effect). Transient blood pressure decrease (common). Injection site reactions (uncommon)
What is the PT-141 cycle protocol?
PT-141 is typically cycled as needed. Max 8 times per month, 24-hour minimum between doses
Questions reflect common community inquiries. This is not medical advice.